Infusion Center Consulting: Feasibility, Chair Planning & 340B

Infusion center consulting helps hospitals, health systems and independent specialty practices assess whether a proposed infusion program is operationally practical and financially sustainable. A sound plan connects patient demand with chair capacity, staffing, payer contracts, drug acquisition costs, reimbursement, authorization workflows and the requirements that apply to the selected care setting. For organizations considering 340B, it also tests whether the planned covered entity and location meet the applicable program requirements. The point is not to promise a certain profit or launch date; it is to identify the assumptions that need to hold before capital is committed.

A practical review should answer three questions: Is there enough appropriate patient demand? Can the program deliver care safely and efficiently at a realistic cost? And does the financial model remain viable when actual payer mix, claim delays and changing site-of-care policies are considered? The sections below provide a framework for answering those questions before launch or expansion.

What does infusion center consulting include?

A complete engagement brings market and referral analysis together with operating design and reimbursement modeling. Depending on the organization’s needs, this can include therapy selection, referral mapping, space planning, chair utilization, staffing, payer contracting, drug purchasing, billing, prior authorization, cash-flow planning and compliance readiness. A startup and an established center rarely need the same intervention: a new program may need a feasibility assessment, while an existing site may need to understand why empty chair time, denials or low reimbursement are eroding performance.

For hospitals and health systems, the model should connect the proposed service line with current capacity and the system’s broader care strategy. For independent practices, ambulatory infusion center consulting may need to place greater emphasis on payer contracts, working capital, staffing flexibility and the operational support the practice can realistically sustain. The right scope is specific to the decision being made — not a generic checklist sold to every facility.

Infusion center feasibility study: validate demand before choosing a site

An infusion center feasibility study should begin with the clinical and referral opportunity, not with a floor plan. Define the patient populations and therapies the center intends to serve. Review historical infusion volume when available, referring-provider patterns, likely referral commitments, local alternatives, travel distance, payer network participation and treatment frequency. Separate confirmed referral evidence from assumptions about how many patients might use a new location.

The next step is to estimate how demand will develop over time. A new program may open with lower utilization than its long-term target, and authorization delays, cancellations, incomplete orders or patient preferences can slow the ramp. Model a conservative case, a base case and an upside case. For each, record the assumed number of referrals, share converted to scheduled treatments, treatments completed, average treatment duration, operating days and seasonal or specialty-specific variation.

A useful feasibility study also tests alternatives. Would a smaller opening footprint, a phased launch or a different setting reduce exposure without limiting appropriate access? Can existing space or capacity be used before signing a long lease? What volume and operational milestones would need to be reached before adding chairs or extending hours? These questions make the study a decision tool rather than a document that simply supports a preferred plan.

How many chairs does an infusion center need?

The answer to how many chairs does an infusion center need depends on demand and chair-hours — not simply the room size or a competitor’s layout. Treatments differ in duration, monitoring requirements, preparation time and turnover. A short injection, a one-hour infusion and a multi-hour infusion use capacity very differently, even if each is recorded as one visit.

Start by estimating completed visits by therapy and day of week. Multiply the forecast volume by the expected chair time for each treatment, then add realistic preparation, turnover and schedule buffers. Compare the resulting chair-hours with the center’s proposed operating hours. Finally, test whether trained clinical staff, medication preparation, authorization clearance and front-office capacity can support the schedule. The physical chair count should follow this operating model.

Do not use a fixed number of patients per chair per day as a universal benchmark. Actual throughput depends on case mix, treatment lengths, arrival patterns, staffing and the center’s clinical model. Use local operational data where possible, and document assumptions when local data do not yet exist. The model should also show what happens when demand is lower than expected or more treatments run longer than planned.

Use the site’s Infusion Center Economics Model to support scenario planning, then reconcile the assumptions with the facility’s own referrals, schedules, payer contracts and staffing plan. A model is only as reliable as its inputs.

Is an infusion center profitable? Build a realistic monthly model

The question is an infusion center profitable has no single answer that applies to every market or specialty. Results depend on therapy mix, payer mix, contracted reimbursement, drug acquisition cost, chair utilization, staffing, rent and other overhead, claim denials, patient cost-sharing and the time it takes to collect cash. Two centers with similar chair counts can perform very differently when their contracts, patient populations or service mix differ.

Build a monthly pro forma for at least the planned ramp-up period and a longer view that reflects the business decision. Show startup costs, fixed and variable expenses, expected drug purchasing, staffing by shift, revenue by payer or service where credible data exist, and the timing of collections. Do not treat billed charges or estimated reimbursement as cash received. Include scenarios for lower volume, slower referral growth, delayed authorization, denied claims, reimbursement changes and drug wastage where applicable.

A useful breakeven month calculation identifies the conditions under which operating revenue covers the relevant costs; it does not turn a forecast into a guarantee. Show the assumptions that move the result most, the working capital required before collections stabilize and the management actions that will be taken if actual performance falls below plan. Update the model with actual results after launch rather than continuing to rely on the original forecast.

Payer mix and buy-and-bill risk

Payer mix is the distribution of covered lives or treatments across commercial insurance, Medicare, Medicaid and other payment arrangements. Reimbursement may vary by contract, drug, administration service, place of service and applicable payment policy. A model that uses one average reimbursement number can conceal the economics of individual therapies or payer arrangements. Use current contracts and reliable claims data whenever possible, and clearly label estimates when contract-specific information is not available.

In a buy and bill arrangement, the provider purchases the medication, administers it and then bills the payer. The provider therefore takes on exposure between drug purchase and payment. That gap can be particularly important when acquisition costs are high, payer adjudication is slow or a claim needs correction. Forecast the cash required to fund inventory, the expected collection timeline, denial and appeal workload, and the effect of delayed payments on the next cycle of drug purchasing.

Evaluate the whole process, not just the apparent difference between acquisition cost and reimbursement. A margin estimate may fail to translate into collected cash if the drug was not authorized correctly, the claim used the wrong code or units, documentation was incomplete or follow-up did not happen promptly. A focused review of revenue recovery and optimization can help teams investigate the administrative and revenue-cycle side of the model.

J-code billing and prior authorization: design workflows before go-live

Many provider-administered drugs are reported using HCPCS Level II codes, including J-codes where applicable. J-code billing requires attention to the specific drug, unit definition, documentation, administration services and payer rules. Code and unit errors can contribute to denials or underpayments. There is no safe universal shortcut: billing staff should use current coding references and confirm the requirements that apply to the medication and payer.

Prior authorization should be a defined workflow with a named owner, a way to track status, clear escalation steps and timely communication with the ordering clinician and patient. Incomplete orders or delayed approvals can lead to last-minute cancellations and empty chair time. Measure authorization turnaround, missing-document rates, denial reasons and rescheduling to understand where the process is failing. Build these tasks into staffing and technology decisions before the first treatment is scheduled.

Also define the handoffs between clinical staff, scheduling, medication procurement, coding and billing. Teams should know who confirms eligibility, who obtains authorization, who checks that the planned treatment matches the approval, and who follows up on a rejected or underpaid claim. Clear ownership helps protect both patient access and the financial model.

340B infusion center planning: confirm eligibility before assuming savings

A 340B infusion center model may change the drug acquisition assumptions for a qualifying covered entity, but eligibility should not be inferred from a hospital affiliation or from the fact that treatment occurs off campus. The proposed entity, location, registration status and operating arrangement must be evaluated against the requirements that apply to the program. In particular, off-site hospital outpatient facilities that intend to use or purchase 340B drugs may need to be registered and supported by the relevant cost-report information.

Model the financial impact only after the organization has confirmed the relevant eligibility assumptions with qualified 340B personnel and current program guidance. Keep the operational controls in view: patient eligibility documentation, purchasing and inventory records, prevention of diversion and duplicate discounts, exception handling, and ownership of audit requests. A forecast that assumes 340B savings before validating the site and workflow can overstate the business case.

Juris 340B Solutions’ 340B compliance services and its overview of what the 340B Program is are relevant supporting pages for organizations assessing these requirements. Where the program applies, the infusion plan should connect with the organization’s wider controls rather than treating compliance as a later administrative task. For a readiness check, review the 340B mock audit service.

Hospital outpatient infusion vs freestanding: compare the full model

The choice between hospital outpatient infusion vs freestanding is a strategic decision, not just a comparison of facility fees or rent. The settings may differ in payment methodology, contracts, staffing structure, overhead, regulatory requirements, patient convenience, referral access and 340B implications. Payment and operating assumptions depend on the actual site, service and payer; do not assume that one setting always reimburses better or is always less expensive.

Compare total economics across both models. Include staffing and clinical coverage, space costs, medication acquisition, payer participation and authorization rules, administrative infrastructure, transportation and access, and the impact of any site-of-care policies that redirect treatment. If a move or off-site launch is being considered, confirm its effect on applicable registrations and covered-entity requirements before using a 340B benefit in the forecast.

A site of care decision can also change over time as payer policies and contracts change. Review the site’s therapy mix for exposure to redirection, white-bagging or other drug-sourcing rules, and test how the model performs if a portion of volume moves to another setting. The related Juris article on site-of-care and white bagging is the natural internal next read for this topic.

Staffing and nurse to chair ratio: plan around acuity and workflow

A nurse to chair ratio should never be copied from another facility without checking the patient population, therapy complexity, monitoring needs, emergency readiness, applicable state requirements and organizational policies. The staffing model should reflect more than the minutes a patient occupies a chair. It also has to cover assessment, medication checks, monitoring, documentation, patient education, coordination and turnover.

Forecast the staffing needed by shift and workload, then test it against both the conservative and expected demand scenarios. Too little coverage can place patients and staff at risk; excessive staffing relative to actual demand can strain the financial plan. A safe staffing assessment should be led by qualified clinical leadership and revisited as therapy mix, operating hours and utilization change.

NICA accreditation and operational quality readiness

Organizations considering NICA accreditation should review the current standards and process published by the National Infusion Center Association (NICA), along with relevant state, payer and facility requirements. NICA describes its standards as a framework for quality and safety in ambulatory infusion care. Do not assume accreditation is universally required for reimbursement or that obtaining it guarantees payer participation; confirm the requirements relevant to the specific setting and contracts.

Quality readiness should be built into the operating plan through written policies, staff training and competency, medication handling, emergency preparedness, documentation, patient communication and a quality-improvement process. Treat these as core launch requirements, not a final checklist to complete after the center begins seeing patients.

Infusion center startup consulting: a launch sequence that reduces avoidable surprises

Effective infusion center startup consulting usually starts with decisions in a logical order. The sequence below is a planning framework; each organization must validate the exact licensing, enrollment, clinical and facility requirements that apply in its state and setting.

1. Validate patient demand and referral assumptions before committing to a site or large footprint.
2. Compare facility and care-setting options, including payer contracts, patient access and any relevant 340B eligibility questions.
3. Build a financial model with chair-hours, staffing, payer mix, drug acquisition, startup costs, working capital and downside scenarios.
4. Confirm applicable clinical, facility, licensing, enrollment and payer requirements with qualified professionals and relevant authorities.
5. Design scheduling, eligibility checks, authorization, coding, billing, denial follow-up and cash-collection workflows before go-live.
6. If 340B may apply, validate eligibility and registration and assign clear ownership for documentation, purchasing controls and audit readiness.
7. Launch at a scope the team can support safely, then use actual demand, utilization, reimbursement and cash data to guide expansion.

Common planning mistakes to avoid

• Choosing a chair count before validating referrals, therapy duration and achievable chair-hours.
• Using a hoped-for payer mix instead of contract-level assumptions and scenario analysis.
• Treating gross billed revenue as collected cash or assuming that drug spread alone determines profitability.
• Underestimating working capital needed while high-cost drugs and delayed claims move through the revenue cycle.
• Leaving prior authorization, coding, denial follow-up or 340B exception management without a named owner.
• Assuming that an off-site or affiliated clinic automatically qualifies for 340B pricing.
• Presenting a single break-even date without stating the volume, staffing and reimbursement assumptions behind it.
• Expanding before actual utilization and safe staffing data support the additional capacity.